ORM-15341 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a selective androgen receptor degrader (SARD), which targets and degrades androgen receptors in cancer cells. This mechanism is particularly relevant in the treatment of prostate cancer, where androgen receptors play a critical role in tumor growth and progression. By degrading these receptors, ORM-15341 aims to inhibit the proliferation of cancer cells and potentially slow down or halt the disease's advancement. Research is ongoing to evaluate its efficacy, safety, and potential as a novel treatment option for patients with advanced or resistant forms of prostate cancer.